Travere Therapeutics Reports First Quarter 2022 Financial Results Submitted New Drug Application (NDA) for sparsentan in IgA nephropathy in March 2022 Results from Phase 1/2 COMPOSE Study of pegtibatinase in classical homocystinuria (HCU) presented at the Society...

Travere Therapeutics Announces Positive Topline Results from the Ongoing Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria Treatment with highest dose pegtibatinase led to a clinically meaningful 55% mean reduction in total homocysteine from baseline and was generally well-tolerated after 12 weeks of treatment Results...

Travere Therapeutics Reports Second Quarter 2021 Financial Results Company expects to submit an application for conditional marketing authorization of sparsentan for FSGS in Europe before year-end 2021 Pivotal PROTECT Study of sparsentan in IgA nephropathy on track...

Travere Therapeutics to Present at Upcoming Investor Conferences SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the following upcoming virtual investor conferences in...

Travere Therapeutics Announces Pricing of Public Offering of Common Stock SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 6,550,000 shares of its common stock at a...